Aridis Pharmaceuticals, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on discovering and developing highly differentiated immunotherapy drug candidates to prevent and treat life-threatening infectious diseases, particularly severe respiratory infections. Its core products include fully human monoclonal antibodies such as AR-301 and AR-320 targeting Staphylococcus aureus alpha-toxin for the treatment and prevention of ventilator-associated pneumonia (VAP), AR-501, an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity for treating chronic lung infections in cystic fibrosis patients, AR-201 targeting respiratory syncytial virus, and AR-701, a cocktail of fully human monoclonal antibodies developed from convalescent COVID-19 patients aimed at SARS-CoV-2. The company employs proprietary technology platforms, including ⅄PEX and MabIgX®, to rapidly identify and develop therapeutic monoclonal antibodies. Founded in 2003 and headquartered in Los Gatos, California, Aridis operates primarily in the United States with global aspirations in infectious disease therapeutics. Recent major company developments include the execution of an Asset Acquisition Terms Agreement for AR-501, with expected payments of $6.5 million in early 2025 plus future royalties, a proposed investment from a global private firm to complete the final Phase 3 study of AR-301, and a corporate strategy to reduce expenses while advancing clinical programs. AR-301 has completed a pivotal Phase 3 trial showing promise, especially in elderly patients with ventilator-associated pneumonia. AR-320's Phase 3 trial is currently on hold due to a licensing dispute. AR-501 completed its Phase 2a clinical development successfully addressing lung infections in cystic fibrosis patients. The company continues to pursue partnerships, funding, and regulatory agreements for its product pipeline including ongoing dialogues with pharmaceutical firms and investors. Through these activities, Aridis aims to redefine standards of care for infectious respiratory diseases by expanding therapeutic options beyond current antibiotics and antiviral treatments. This comprehensive business includes research and development of targeted immunotherapies, clinical trials, and strategic collaborations focused on severe infectious diseases with a specialty in respiratory conditions. Aridis leverages its strong intellectual property portfolio and scientific expertise to develop novel, differentiated therapies that address antimicrobial resistance and viral pandemics. Its main customer segments are healthcare providers and institutions managing severe respiratory infections and chronic lung conditions. The company's development pipeline, technology platforms, and clinical-stage assets position it for growth in the global biopharmaceutical infectious disease market. Aridis Pharmaceuticals, Inc. remains publicly traded under the ticker ARDS and is actively engaged in advancing late-stage clinical programs and securing collaborations to strengthen its development and commercialization capabilities. Its recent operational shifts emphasize regulatory progress, clinical trial management, and financial optimization to deliver on its strategic growth objectives in infectious disease therapeutics.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Aridis Provides Corporate Update
Aridis Provides Corporate Update
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Aridis Pharmaceuticals Announces $2 Million Offering
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
5 Hot Penny Stocks To Watch With Big News This Week
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates